Please assess the completion status of the following clinical trial:

Trial Title: Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PRP by clinical assessment and biopsy.~* Male subject age 18-99.~* Female subject age 18-99; either of non-childbearing potential or of childbearing potential who test negative for pregnancy and agree to use a reliable method of birth control or remain abstinent during the study and for at least 12 weeks following the last dose of ixekizumab.~* PASI score of 10 or greater at baseline.~* Are a candidate for phototherapy and/or systemic therapy.~* Willingness to travel to OHSU for all study visits, OR living \>30 miles from OHSU and willing/able to participate in remote videoconferencing visits with access to a computer with internet capabilities and webcam.~* Have given written informed consent approved by the OHSU Investigational Review Board.~Exclusion Criteria:~* Known malignancy or lymphoproliferative disease (except treated basal cell skin cancer, treated squamous cell skin cancer, or treated cervical carcinoma in situ) for at least 5 years.~* Active, untreated, acute or chronic infection (such as untreated tuberculosis), or immunocompromised to an extent that such that participation in the study would pose an unacceptable risk to the subject. (Treated infections such as latent tuberculosis after completion of the appropriate therapy are not excluded.)~* Positive for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus.~* Previous treatment with any agent that targets interleukins 17 specifically.~* Systemic treatment or phototherapy for PRP within the past 4 weeks or 5 half-lives prior to baseline, whichever is longer. For biologic therapies, the specific washout periods used will be: etanercept \<28 days; infliximab, adalimumab, or alefacept \<60 days; golimumab \<90 days; ustekinumab \<8 months; rituximab or efalizumab \<12 months.~* Have a known allergy or hypersensitivity to any biologic therapy that would pose an unacceptable risk to the subject if participating in this study.~* Have a live vaccine within 12 weeks prior to baseline or intend to have a live vaccine during the course of study.~* Had any major surgery within 8 weeks prior to baseline or will require major surgery during the study that, in the opinion of the investigator, would pose an unacceptable risk to the subject.~* Presence of significant uncontrolled cerebrovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic, or neuropsychiatric disorders, or abnormal laboratory screening values that, in the opinion of the investigator, pose an unacceptable risk to the subject if participating in the study or of interfering with the interpretation of the data.~* Presence of inflammatory bowel disease~* Have clinical laboratory test results at screening that are outside the normal reference range of the population and are considered clinically significant, or have any of the following specific abnormalities: Neutrophil count \<1500 cells/µL, lymphocyte count \<500 cells/µL, platelet count \<100,000 cells/µL, AST or ALT \> 2.5 times the upper limit of normal, hemoglobin \<8.5 g/dL for male subjects and \<8.0 g/dL for female subjects, serum creatinine \>2.0 mg/dL.~* Women who are lactating or breastfeeding.~* Have any other condition that precludes the subject from following and completing the protocol, in the opinion of the investigator.~* Are investigator site personnel directly affiliated with this study and/or their immediate families (spouse, parent, child, or sibling).~Are currently enrolled in, or discontinued from a clinical trial involving an investigational product or non-approved use of a drug or device within the last 4 weeks or a period of at least 5 half-lives of the last administration of the drug, whichever is longer, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Ixekizumab treatment arm (Type: EXPERIMENTAL): Ixekizumab 160 mg subcutaneous injection at week 0, followed by 80 mg subcutaneous injections at week 2, 4, 6, 8, 10, 12, 16, and 20

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete